These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6758224)

  • 1. A comparative trial of Mefloquine and Fansidar in the treatment of falciparum malaria: failure of Fansidar.
    Dixon KE; Williams RG; Pongsupat T; Pitaktong U; Phintuyothin P
    Trans R Soc Trop Med Hyg; 1982; 76(5):664-7. PubMed ID: 6758224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria.
    Ekue JM; Phiri DE; Sheth UK; Mukunyandela M
    Bull World Health Organ; 1987; 65(3):369-73. PubMed ID: 3311440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria.
    Hall AP; Doberstyn EB; Karnchanachetanee C; Samransamruajkit S; Laixuthai B; Pearlman EJ; Lampe RM; Miller CF; Phintuyothin P
    Br Med J; 1977 Jun; 1(6077):1626-8. PubMed ID: 326337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fansidar resistant falciparum malaria acquired in South East Asia.
    Black F; Bygbjerg I; Effersøe P; Gomme G; Jepsen S; Jensen GA
    Trans R Soc Trop Med Hyg; 1981; 75(5):715-6. PubMed ID: 7036431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose.
    Harinasuta T; Bunnag D; Vanijanond S; Charoenlarp P; Suntharasmai P; Chitamas S; Sheth UK; Wernsdorfer WH
    Bull World Health Organ; 1987; 65(3):363-7. PubMed ID: 3311439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of malaria tropicameningoencephalitis (neuromalaria) with chloroquine and pyrimethamine/sulfadoxine resistance].
    Niklewski G; Landscheidt H; Glasner H
    Nervenarzt; 1985 Feb; 56(2):101-5. PubMed ID: 3885058
    [No Abstract]   [Full Text] [Related]  

  • 7. [Plasmodium falciparum drug resistance and sulfadoxine-pyrimethamine in Africa].
    Randriamanjaka JR; Le Bras J; Charmot G; Coulaud JP
    Bull Soc Pathol Exot Filiales; 1989; 82(3):381-4. PubMed ID: 2670291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fansimef [Fansidar plus mefloquine] is effective treatment for imported malaria in New Zealand.
    Ellis-Pegler RB; Beeching NJ; Eales M; Fraser AG; Wells AU
    Aust N Z J Med; 1988 Aug; 18(5):733-4. PubMed ID: 3072955
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase II/III double-blind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimef) in falciparum malaria.
    de Souza JM; Sheth UK; Wernsdorfer WH; Trigg PI; Doberstyn EB
    Bull World Health Organ; 1987; 65(3):357-61. PubMed ID: 3311438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fansidar-resistant Plasmodium falciparum infection from Tanzania.
    Vleugels MP; Wetsteyn JC; Meuwissen JH
    Trop Geogr Med; 1982; 34(3):263-5. PubMed ID: 6758246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Falciparum malaria acquired in the area of the Thai-Khmer border resistant to treatment with Fansidar.
    Johnson DE; Roendej P; Williams RG
    Am J Trop Med Hyg; 1982 Sep; 31(5):907-12. PubMed ID: 6751111
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of fansidar-resistant Plasmodium falciparum from Tanzania.
    De Geus A; Meuwissen JH; van Rijn A
    Trop Geogr Med; 1982; 34(3):261-3. PubMed ID: 6758245
    [No Abstract]   [Full Text] [Related]  

  • 13. Falciparum malaria resistant to chloroquine and fansidar: implications for prophylaxis.
    Herzog C; Kibbler CC; Ellis CJ; Mtawali CV
    Br Med J (Clin Res Ed); 1983 Oct; 287(6397):947-8. PubMed ID: 6412900
    [No Abstract]   [Full Text] [Related]  

  • 14. [Uncomplicated malaria attack in an area with high resistance to chloroquine. 3. The use of second-choice oral drug treatment].
    Hengy C; Eberlé F; Gazin P; Kouka-Bemba D; Gelas H; Jambou R
    Bull Soc Pathol Exot; 1990; 83(1):61-5. PubMed ID: 2190706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of sulfadoxine-pyrimethamine in the treatment of falciparum malaria in Sabah, Malaysia.
    Tan HS; Tan PE
    Ann Acad Med Singap; 1984 Apr; 13(2):170-4. PubMed ID: 6388486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment failure of falciparum malaria with Fansidar in Tawau Sabah. January-June, 1982.
    Tan Heng Soon ; Tan Puay Eng
    Med J Malaysia; 1983 Sep; 38(3):217-23. PubMed ID: 6369092
    [No Abstract]   [Full Text] [Related]  

  • 17. Qinghaosu, mefloquine, and pyrimethamine-sulfadoxine in falciparum malaria.
    Arnold K
    Lancet; 1985 Mar; 1(8430):704. PubMed ID: 2858655
    [No Abstract]   [Full Text] [Related]  

  • 18. An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil.
    de Souza JM; Sheth UK; de Oliveira RM; Roulet H; de Souza SD
    Bull World Health Organ; 1985; 63(3):603-9. PubMed ID: 3899397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of Plasmodium falciparum to mefloquine-sulphadoxine-pyrimethamine (Fansimef) in vivo and to mefloquine alone in vitro in Nigeria.
    Salako LA; Aderounmu AF; Laoye JO; Makinde JM; Adio RA
    Ann Trop Med Parasitol; 1988 Aug; 82(4):325-30. PubMed ID: 3075441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria.
    Fadeke Aderounmu A; Salako LA; Laoye AJ; Modupe Makinde J; Aina Adio R
    Afr J Med Med Sci; 1988 Dec; 17(4):195-200. PubMed ID: 2854365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.